Review



aptt reagent trinclot hs  (Trinity Biotech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Trinity Biotech aptt reagent trinclot hs
    Clinical and Laboratory Characteristics of Heparin Treated Patients
    Aptt Reagent Trinclot Hs, supplied by Trinity Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aptt+reagent+trinclot+hs/pmc03153569-62-0-4?v=Trinity+Biotech
    Average 90 stars, based on 1 article reviews
    aptt reagent trinclot hs - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients"

    Article Title: Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients

    Journal: Thrombosis research

    doi: 10.1016/j.thromres.2011.03.021

    Clinical and Laboratory Characteristics of Heparin Treated Patients
    Figure Legend Snippet: Clinical and Laboratory Characteristics of Heparin Treated Patients

    Techniques Used: Biomarker Discovery

    A. Concentration dependence of T18R virus-like particle reversal of heparin-prolonged aPTT. B. Concentration dependence of K16M virus-like particle reversal of heparin-prolonged aPTT. C. Percent heparin reversal in patient plasmas. Virus-like particle was added at 180 μg/ml in plasma, T18R (Δ), K16M (○).
    Figure Legend Snippet: A. Concentration dependence of T18R virus-like particle reversal of heparin-prolonged aPTT. B. Concentration dependence of K16M virus-like particle reversal of heparin-prolonged aPTT. C. Percent heparin reversal in patient plasmas. Virus-like particle was added at 180 μg/ml in plasma, T18R (Δ), K16M (○).

    Techniques Used: Concentration Assay, Virus, Clinical Proteomics

    aPTT of plasma are presented after incubation with varying concentrations of protamine or T18R VLP. Plasma samples were collected from six patients before (control without heparin) and during (every 30 minutes) the coronary procedure. A. Protamine correction of aPTT prolongation of individual patient samples. B. T18R VLP correction of aPTT prolongation of individual patient samples. C. Average correction of aPTT prolongation of patient samples, protamine (■), n=14, T18R VLP (▲), n=12. Error bars = SD. D. aPTT of control patient samples without heparin, protamine (■), T18R VLP (▲). A reference aPTT value (47.2 sec) that is the average aPTT value for control patient plasmas without added heparin or VLP is indicated as a ● at X = 0 in panels A, B and C.
    Figure Legend Snippet: aPTT of plasma are presented after incubation with varying concentrations of protamine or T18R VLP. Plasma samples were collected from six patients before (control without heparin) and during (every 30 minutes) the coronary procedure. A. Protamine correction of aPTT prolongation of individual patient samples. B. T18R VLP correction of aPTT prolongation of individual patient samples. C. Average correction of aPTT prolongation of patient samples, protamine (■), n=14, T18R VLP (▲), n=12. Error bars = SD. D. aPTT of control patient samples without heparin, protamine (■), T18R VLP (▲). A reference aPTT value (47.2 sec) that is the average aPTT value for control patient plasmas without added heparin or VLP is indicated as a ● at X = 0 in panels A, B and C.

    Techniques Used: Clinical Proteomics, Incubation, Control



    Similar Products

    aptt reagent trinclot hs  (Trinity Biotech)
    90
    Trinity Biotech aptt reagent trinclot hs
    Clinical and Laboratory Characteristics of Heparin Treated Patients
    Aptt Reagent Trinclot Hs, supplied by Trinity Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aptt+reagent+trinclot+hs/pmc03153569-62-0-4?v=Trinity+Biotech
    Average 90 stars, based on 1 article reviews
    aptt reagent trinclot hs - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Clinical and Laboratory Characteristics of Heparin Treated Patients

    Journal: Thrombosis research

    Article Title: Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients

    doi: 10.1016/j.thromres.2011.03.021

    Figure Lengend Snippet: Clinical and Laboratory Characteristics of Heparin Treated Patients

    Article Snippet: APTT reagent (Triniclot HS, Trinity Biotech, Bray, Ireland) was then added and the reaction was incubated at 37 °C for 3 minutes before initiation of coagulation with CaCl 2 .

    Techniques: Biomarker Discovery

    A. Concentration dependence of T18R virus-like particle reversal of heparin-prolonged aPTT. B. Concentration dependence of K16M virus-like particle reversal of heparin-prolonged aPTT. C. Percent heparin reversal in patient plasmas. Virus-like particle was added at 180 μg/ml in plasma, T18R (Δ), K16M (○).

    Journal: Thrombosis research

    Article Title: Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients

    doi: 10.1016/j.thromres.2011.03.021

    Figure Lengend Snippet: A. Concentration dependence of T18R virus-like particle reversal of heparin-prolonged aPTT. B. Concentration dependence of K16M virus-like particle reversal of heparin-prolonged aPTT. C. Percent heparin reversal in patient plasmas. Virus-like particle was added at 180 μg/ml in plasma, T18R (Δ), K16M (○).

    Article Snippet: APTT reagent (Triniclot HS, Trinity Biotech, Bray, Ireland) was then added and the reaction was incubated at 37 °C for 3 minutes before initiation of coagulation with CaCl 2 .

    Techniques: Concentration Assay, Virus, Clinical Proteomics

    aPTT of plasma are presented after incubation with varying concentrations of protamine or T18R VLP. Plasma samples were collected from six patients before (control without heparin) and during (every 30 minutes) the coronary procedure. A. Protamine correction of aPTT prolongation of individual patient samples. B. T18R VLP correction of aPTT prolongation of individual patient samples. C. Average correction of aPTT prolongation of patient samples, protamine (■), n=14, T18R VLP (▲), n=12. Error bars = SD. D. aPTT of control patient samples without heparin, protamine (■), T18R VLP (▲). A reference aPTT value (47.2 sec) that is the average aPTT value for control patient plasmas without added heparin or VLP is indicated as a ● at X = 0 in panels A, B and C.

    Journal: Thrombosis research

    Article Title: Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients

    doi: 10.1016/j.thromres.2011.03.021

    Figure Lengend Snippet: aPTT of plasma are presented after incubation with varying concentrations of protamine or T18R VLP. Plasma samples were collected from six patients before (control without heparin) and during (every 30 minutes) the coronary procedure. A. Protamine correction of aPTT prolongation of individual patient samples. B. T18R VLP correction of aPTT prolongation of individual patient samples. C. Average correction of aPTT prolongation of patient samples, protamine (■), n=14, T18R VLP (▲), n=12. Error bars = SD. D. aPTT of control patient samples without heparin, protamine (■), T18R VLP (▲). A reference aPTT value (47.2 sec) that is the average aPTT value for control patient plasmas without added heparin or VLP is indicated as a ● at X = 0 in panels A, B and C.

    Article Snippet: APTT reagent (Triniclot HS, Trinity Biotech, Bray, Ireland) was then added and the reaction was incubated at 37 °C for 3 minutes before initiation of coagulation with CaCl 2 .

    Techniques: Clinical Proteomics, Incubation, Control